pcMSC Modulates Immune Dysregulation in Patients With COVID-19-Induced Refractory Acute Lung Injury

pcMSC Modulates Immune Dysregulation in Patients With COVID-19-Induced Refractory Acute Lung Injury

Background and ObjectivesThe novel coronavirus disease 2019 (COVID-19) has been a pandemic health issue in 30 January 2020. The mortality rate is as high as 50% in critically ill patients. Stem cell therapy is effective for those who are refractory to standard treatments. However, the immune respons...

ver descrição completa

Detalhes bibliográficos
Main Authors: Mei-Chuan Chen, Kevin Shu-Leung Lai, Ko-Ling Chien, Sing Teck Teng, Yuh-Rong Lin, Wei Chao, Meng-Jung Lee, Po-Li Wei, Yen-Hua Huang, Han-Pin Kuo, Chih-Ming Weng, Chun-Liang Chou
Formato: Artigo
Idioma:English
Publicado em: Frontiers Media S.A. 2022-04-01
Colecção:Frontiers in Immunology
Assuntos:
COVID-19
mesenchymal stem cell
severe lung injury
immune response
Treg cells
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fimmu.2022.871828/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.871828/full

Registos relacionados